chevrons

Back to Previous Page

Company Quarterly Earnings Update – DHG VN – 2020 9M

Summary of the 2020 9M results of Hau Giang Pharmaceutical JSC (DHG VN)

9M/2020 results highlights:
  • Net revenue was VND2,543bn, -2.8% y/y mostly due to changes in booking policy, while net profit posted 24.3% y/y growth, generally in line with our expectation. The main cause for the decline in revenue was a change in commission form for distributors. Since Q2, travel packages, which were usually offered as commissions for distributors, could not be held due to travel restrictions amidst the pandemic. As a result, DHG lowered its selling prices instead. Despite a second Covid-19 outbreak in July, businesses have resumed normal activities thanks to the government’s effective containment of the pandemic. Consequently, Q3 enjoyed a moderate sales growth of 5.5% y/y.
  • Gross margin saw an increase to 48.8%, up from 44.0% in 9M/2019. The main reasons were 1) higher contribution of own-product revenue, and 2) certain highmargin products were in higher demand.
  • The financial position remained solid: cash and deposits were 48.4% of total assets, and leverage was minimal (D/E and D/A of 0.15x and 0.12x, respectively).
Outlook
  • For 2020, our last full year estimates are mostly unchanged. As such, revenue is expected at VND3,644bn (-6.5% y/y) and net profit at VND715bn (+13.3% y/y). Although the pandemic is still spreading in other regions of the world, we believe that business activities will likely recover based on the prospect that vaccines will be commercially available next year after the recent successful tests.
  • For 2021, we project revenue growth of 8.7% and net profit growth of 10.8% y/y on the back of long-term growth drivers that include increases in product offerings and improved product quality with Taisho’s support.
Recommendation

Company ratings and target prices are accessible for clients only.

If you are interested in getting full access to our paid Primary Research Materials feel free to get in touch with us at your convenience.

Our team is actively covering 50 companies in the listed Vietnamese equity space for our clients.


Featured image credit: ndh.vn

Related News & Insights
Find out more navigation_button
news

Summary of Q1 2026 results and outlook of Binh Dinh Pharmaceutical and Medical Equipment JSC (DBD VN) Net revenue rose 1.6% y/y to VND448bn. Growth was led by kidney dialysis products (+11.8% y/y), minerals, vitamins & supplements (+29.4% y/y), and psychiatric & neurological disorder therapies (+20.5% y/y). Oncology products (+1.5% y/y) and antibiotics (-15.2% y/y) […]

Read Newsarrow
news

Summary of Q1 2026 results and outlook of Nam Long Investment (NLG VN) The real estate market continued to record an increase in new supply, supported by the ongoing easing of legal procedures. However, supply-demand imbalances persist in major cities, where new launches remain concentrated in the high-end and luxury segments. On the demand side, […]

Read Newsarrow
news

Summary of Q1 2026 results and outlook of Phuoc Hoa Rubber JSC (PHR VN) PHR operates two core business lines: (1) rubber plantation and natural rubber sales, and (2) the conversion of plantation land for IP development. Net profit increased 177.4% y/y to VND285bn, mainly driven by the IP segment, where profit rose 4.9x y/y […]

Read Newsarrow
Find out more navigation_button